These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 19728887

  • 21. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 22. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

  • 23. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
    Silver MR, Geronemus R, Krause M, Chen CY, Kewalramani R, Stehman-Breen C.
    Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145
    [Abstract] [Full Text] [Related]

  • 24. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE.
    Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
    [Abstract] [Full Text] [Related]

  • 25. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 26. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group.
    J Natl Cancer Inst; 2002 Aug 21; 94(16):1211-20. PubMed ID: 12189224
    [Abstract] [Full Text] [Related]

  • 27. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun 21; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

  • 28. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
    Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M.
    Nephrol Dial Transplant; 2012 Jun 21; 27(6):2303-11. PubMed ID: 22140136
    [Abstract] [Full Text] [Related]

  • 29. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May 21; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 30. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar 21; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 31. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
    Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C.
    Am J Geriatr Pharmacother; 2008 Jun 21; 6(2):49-60. PubMed ID: 18675764
    [Abstract] [Full Text] [Related]

  • 32. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T.
    Am J Nephrol; 2021 Jun 21; 52(10-11):884-893. PubMed ID: 34569482
    [Abstract] [Full Text] [Related]

  • 33. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K.
    Am J Hematol; 2010 Sep 21; 85(9):655-63. PubMed ID: 20661916
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 21; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 35. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Jun 21; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 36. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
    Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C.
    J Thorac Oncol; 2020 Feb 21; 15(2):190-202. PubMed ID: 31629060
    [Abstract] [Full Text] [Related]

  • 37. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.
    Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF, Nikcevich D, Loprinzi CL.
    Am J Hematol; 2015 Oct 21; 90(10):877-81. PubMed ID: 26149465
    [Abstract] [Full Text] [Related]

  • 38. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G, Llorca C, Cervera JM, Orts D, Juárez A, Carrato A.
    Clin Transl Oncol; 2011 May 21; 13(5):341-7. PubMed ID: 21596663
    [Abstract] [Full Text] [Related]

  • 39. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, Maisano R.
    Support Care Cancer; 2017 Sep 21; 25(9):2779-2786. PubMed ID: 28391437
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
    Nangaku M, Kondo K, Ueta K, Kokado Y, Kaneko G, Matsuda H, Kawaguchi Y, Komatsu Y.
    Nephrol Dial Transplant; 2021 Aug 27; 36(9):1731-1741. PubMed ID: 33650630
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.